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Edited by Robert BaroukiAbstract The purpose of this study was to determine whether
bile acids (BAs) modulate hepatic pro-protein convertase subtil-
isin/kexin 9 (PCSK9) gene expression. Immortalized human
hepatocytes were treated with various BAs. Chenodeoxycholic
acid (CDCA) treatment speciﬁcally decreased both PCSK9
mRNA and protein contents. Moreover, activation of the BA-
activated farnesoid X receptor (FXR) by its synthetic speciﬁc
agonist GW4064 also decreased PCSK9 expression. Of func-
tional relevance, coadministration of CDCA counteracted the
statin-induced PCSK9 expression, leading to a potentiation of
LDL receptor activity. This study suggests that a transcriptional
repression of PCSK9 by CDCA or FXR agonists may potentiate
the hypolipidemic eﬀect of statins.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Pro-protein convertase subtilisin/kexin 9 (PCSK9) has re-
cently emerged as a central player in the regulation of choles-
terol homeostasis [1]. In addition to mutations aﬀecting the
LDL-receptor (LDLr) and apolipoprotein B, ‘‘gain-of-func-
tion’’ PCSK9 mutations lead to an increase of plasma LDL-
cholesterol (LDL-c) levels and premature atherosclerosis
[1,2]. In contrast, ‘‘loss-of-function’’ mutations are associated
with low levels of LDL-c and confer protection against cardio-
vascular disease [3]. PCSK9 is primarily expressed in the liver
and the intestine. PCSK9 inhibits the LDLr activity in a post-
transcriptional manner [1]. Recent data suggest that, onceAbbreviations: BA, bile acid; CA, cholic acid; CDCA, chenodeoxy-
cholic acid; DCA, deoxycholic acid; FXR, farnesoid X receptor; IHH,
immortalized human hepatocytes; LA, lithocholic acid; LDL-c, low
density lipoprotein cholesterol; LDLr, low density lipoprotein recep-
tor; PCSK9, pro-protein convertase subtilisin/kexin 9; PXR, pregnane
X receptor; UDCA, ursodeoxycholic acid
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doi:10.1016/j.febslet.2008.02.038cleaved, secreted PCSK9 acts as a chaperone and promotes
the intracellular degradation of the LDLr by interfering with
its recycling to the plasma membrane [4,5].
Various positive and negative regulatory pathways of
PCSK9 have been identiﬁed. The hypocholesterolemic drugs
statins were shown to increase PCSK9 expression, a pathway
which exerts a break on their eﬃciency [6,7]. In accordance
with this negative feedback pathway, PCSK9-deﬁcient mice
[8] and patients bearing non sense mutations for PCSK9 [9]
are more responsive to statins. Our laboratory characterized
the PCSK9 promoter and showed that PCSK9 is also up-reg-
ulated by insulin as well as by the Liver X Receptor agonist
T0901317 via SREBP-1c [10]. In an opposite way, fenoﬁbrate
decreases hepatic PCSK9 expression in a PPARa-dependent
manner [11].
Bile acids (BAs) are liver-synthesized cholesterol-derivatives
that represent the major route for removal of excess cholesterol
from the body. Besides their role as detergents, it has now been
clearly demonstrated that BAs also exert signalling activities
and regulate gene expression in a variety of tissues, including
liver and intestine, at least partly through the activation of
the farnesoid X receptor (FXR), a member of the nuclear
receptor superfamily of ligand-activated transcription factors
[12,13]. In addition to FXR, BAs can also activate other nucle-
ar receptors such as PXR (pregnane X receptor), CAR (consti-
tutive androstane receptor) and vitamin D receptor [14,15].
Here, we investigated whether BAs can modulate the expres-
sion of PCSK9. We found that chenodeoxycholic acid
(CDCA) speciﬁcally represses PCSK9 expression in immortal-
ized human hepatocytes, thereby potentiating the activity of
the LDLr in response to statins.2. Materials and methods
2.1. Chemicals
BAs (CDCA, UDCA, DCA, CA, LA), pravastatin, rifampicin and
actinomycin D were purchased from Sigma (France). GW4064 was
kindly provided by Genﬁt (Loos, France).
2.2. Cell culture
Immortalized human hepatocytes were cultured on collagen-coated
ﬂasks in Williams E medium in the presence of a 10% fetal calf serum
(FCS). HepG2 cells were cultured in DMEM containing 10% FCS and
1% glutamine. The cells were exposed to various treatments in theblished by Elsevier B.V. All rights reserved.
950 C. Langhi et al. / FEBS Letters 582 (2008) 949–955presence of a 5% lipoprotein deﬁcient serum (LPDS) unless notiﬁed.
For PCSK9 secretion analysis, cells were incubated in 1 ml of medium
without FCS and LPDS. Treatment toxicity was assessed by quantiﬁ-
cation of lactate dehydrogenase activity in cell medium using the
Roche cytotoxicity detection kit (Roche Diagnostics, Indianapolis,
USA).
2.3. Western blots
Proteins were analysed by Western blot as described elsewhere [10],
using a polyclonal rabbit IgG directed against the CRSRHLAGAS-
QELQ peptide (Neosystem, Strasbourg, France), an epitope of the
C-terminal domain of human and mouse PCSK9, or with the mono-
clonal anti b-actin AC-15 antibody (Sigma). For secretion analysis,
proteins from 400 ll of cell culture media were precipitated with ace-
tone.
2.4. RNA extraction and real time PCR
RNA extraction and real time quantitative PCR (Q-PCR) was per-
formed as previously described [10], using the following primers:
LDLR: AAGGCTGTCCCCCCAAGA forward, CGAACTGCC-
GAGAGATGCA reverse; PCSK9: ACGTGGCTGGCATTGCA
forward, AAGTGGATCAGTCTCTGCCTCAA reverse; 18S: AAG-A
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Fig. 1. CDCA reduces PCSK9 mRNA levels in human hepatocytes cell lin
Q-PCR. (A) IHH, cells were incubated for 48 h with 50 lM CDCA, CA,
increasing concentrations (as indicated) of CDCA for 48 h. (C) HepG2 cells w
to 18S mRNA and are expressed (means ± S.E.M.; n = 5) relative to thos
signiﬁcant diﬀerences compared to vehicle-treated cells are indicated (***P <TCCCTGCCCTTTGTACACA forward, CGATCCGAGGGCCTC-
ACTA reverse; UGT2B4: CAACCAGTGAAGCCCCTTGA forward,
GAAGGTGCTTGGCTCCTTTATG reverse; SHP: CTCTTCCT-
GCTTGGGTTGGC forward, GCACATCGGGGTTGAAGAGG
reverse; CYP3A4: CTCTTCACCGTGACCCAAAGTACT forward,
AGCAAACCTCATGCCAATGC reverse.
2.5. Isolation and radiolabelling of LDL
Human LDL (d 1.019–1.063 g/ml) was isolated from plasma of
healthy normolipaemic fasting donors by isopycnic preparative ultra-
centrifugation using a discontinuous KBr density gradient [16]. Iso-
lated LDL was dialysed at least 36 h at 4 C against PBS pH 7.4.
Radiolabelling procedure was performed according to the iodogen
method modiﬁed by Fraker et al. [17].
2.6. Binding of 125I-labelled LDL
IHH cells were incubated for 4 h at 4 C with 10 lg/ml of 125I-
labelled LDL in 250 ll of Williams LPDS 5% containing 4% fatty
acid-free BSA and 50 mM Hepes, pH 7.4. Non-speciﬁc binding was
determined by the addition of 0.5 mg/ml unlabelled LDL. At the end
of the incubation period, the cells were washed three times with 1 ml
of D-PBS containing 1% BSA then three times with 1 ml of D-PBS.8S
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was determined using BSA as a standard, and the radioactivity was
measured (1480 Wizard 300 Automatic Gamma Counter, Wallac, Wal-
tham, Massachusetts, USA). The measured radioactivity was normal-
ized per milligram of cell protein, the speciﬁc binding was calculated by
subtracting the non-speciﬁc binding of 125I-labelled LDL from the to-
tal binding.
2.7. Statistics
Results are representative of at least two independent experiments,
with at least triplicates in each experiment. Statistical signiﬁcance
was analyzed using an unpaired Students t-test. The values of
P < 0.05 were considered signiﬁcant.0.5
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Fig. 2. CDCA ampliﬁes the eﬀect of pravastatin on LDLr activity. IHH cells
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contents were measured by Q-PCR, as described in Fig. 1. Values are mean
protein content analyzed by Western blot and quantiﬁed using Image J 1.37v
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*P < 0.05) or between combined treatment CDCA/pravastatin with CDCA (3. Results
3.1. Repression of PCSK9 by chenodeoxycholic acid in human
hepatocytes
To investigate the eﬀects of BAs on PCSK9 gene expression,
IHH cells were treated for 48 h with a variety of primary
(CDCA, CA, UDCA) and secondary (LA, DCA) BAs at the
concentration of 50 lM (Fig. 1A). Excepted for the LA, these
treatments did not aﬀect the cell toxicity assessed by the level
of the lactate dehydrogenase activity in cell medium (data
not shown). CDCA was found to decrease PCSK9 mRNA0.5
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952 C. Langhi et al. / FEBS Letters 582 (2008) 949–955levels (59%, P < 0.001). In contrast, DCA increased PCSK9
gene expression (+76%, P < 0.001), whereas CA and UDCA
had no eﬀect. Since CDCA is the more potent natural agonist
of FXR [18], the expression of the FXR target-gene UGT2B4
[19] was measured under the same conditions. As expected,
CDCA was the sole BA which signiﬁcantly increased UGT2B4
mRNA levels (Fig. 1A). The eﬀect of BAs treatment on LDLr
expression was also investigated in IHH cells. In accordance
with previous results in HepG2 cells [20], both CDCA and
DCA increased LDLr mRNA levels (+104%, P < 0.001 and
+109%, P < 0.001, respectively) (Fig. 1A). Notably, a strong
induction of LDLr mRNA levels was observed for the higher
dose of CDCA (+544% with 100 lM, P < 0.001) (Fig. 1B).
Conversely, a signiﬁcant and dose-dependent repression of
PCSK9 mRNA levels was observed in IHH cells treated with
various doses of CDCA for 48 h (Fig. 1B). Moreover, this
repression of PCSK9 also occurred in HepG2 cells treated with
50 lM CDCA (87%, P < 0.001) (Fig. 1C). Taken together,
these results demonstrate that CDCA is a new repressor of
PCSK9 gene expression in human hepatocytes.
3.2. CDCA ampliﬁes the eﬀect of pravastatin on LDLr activity
To assess whether PCSK9 upregulation by statins could be
aﬀected by CDCA, we ﬁrst exposed IHH cells to 50 lM
CDCA or DMSO during 24 h before adding or not 5 lM prav-
astatin for an additional 24 h. As expected [6], 24 h treatment
with pravastatin alone increased PCSK9 mRNA levels
(+141%, P < 0.001). Interestingly, pretreatment with CDCA
abolished the induction of PCSK9 gene expression in response
to pravastatin. The statin only slightly increased LDLr gene
expression (+32%, P < 0.01), as described elsewhere [6]. The
combination of both drugs did not further increase LDLr
mRNA levels compared to CDCA treatment alone
(Fig. 2A). In accordance to the mRNA variations, CDCA
strongly reduced the quantity of both intracellular and secreted
PCSK9 protein content, even in the presence of pravastatin
(Fig. 2B). To further investigate whether CDCA functionally
inﬂuences LDLr activity, IHH cells were treated for 48 h with
50 lM CDCA and the surface binding of 125I-labelled human
LDL was assayed (Fig. 2C). Both pravastatin and CDCA
increased the LDLr activity (+72%, P < 0.05 and +204%,
P < 0.001 vs. DMSO, respectively). Interestingly, when a com-
bined treatment with CDCA and pravastatin was performed, am
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signiﬁcant diﬀerences compared to DMSO (***P < 0.001).signiﬁcant 55% (P < 0.05) additional increase in LDLr activity
was observed compared with CDCA alone. Altogether these
data suggest that CDCA potentiates the eﬀect of pravastatin
on LDLr activity by preventing the concomitant induction of
PCSK9 expression.
3.3. CDCA-mediated repression of PCSK9 gene expression
occurs at the transcriptional level
In order to verify the possibility that CDCA reduced PCSK9
mRNA quantity by a process involving mRNA stabilization,
IHH cells were treated for 24 h with either vehicle or 50 lM
CDCA before the transcriptional inhibitor actinomycin D
(5 lg/ml) was added to the medium during the indicated times.
As observed in Fig. 1, CDCA treatment for 24 h decreased
PCSK9 mRNA levels while it concomitantly increased the
expression of SHP, a direct FXR target gene [21]. PCSK9
mRNA half-life was greater than 9 h and was not altered by
CDCA. Under the same experimental conditions, the half-life
of SHP mRNA was less than 3 h and seemed unaltered by
CDCA pre-treatment (Fig. 3). These results suggest that
CDCA acts at the transcriptional level to modulate PCSK9
gene expression.
3.4. Activation of FXR by the synthetic FXR ligand GW4064
represses PCSK9 expression and increases LDLr activity
In order to test whether the regulation of PCSK9 expression
by CDCA depends on FXR activation, IHH cells were treated
by the synthetic FXR agonist GW4064 (Fig. 4A). A dose-
dependent down-regulation of PCSK9 mRNA levels was ob-
served with GW4064 compared to vehicle-treated cells. More-
over, treatment with high doses of GW4064 (P2.5 lM) also
led to a signiﬁcant increase of LDLr mRNA levels. Impor-
tantly, a similar repression of PCSK9 in response to 5 lM
GW4064 was observed in HepG2 cells (88%, P < 0.001)
(Fig. 4B). In accordance with mRNA variations, treatment
with 1 lM GW4064 for 48 h decreased both intracellular and
secreted PCSK9 protein content (Fig. 4C).
Next, we assessed whether the repression of PCSK9 by BAs
can be mediated by the activation of PXR. IHH cells were
treated with rifampicin, a potent PXR ligand [22] (Fig. 4D),
PXR activation led to a dose-dependent increase of PCSK9
gene expression, thus excluding its participation in the
CDCA-mediated repression of PCSK9. While rifampicinSHP/18S
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954 C. Langhi et al. / FEBS Letters 582 (2008) 949–955strongly induced mRNA levels of the PXR target gene
Cyp3A4, it did not alter LDLr mRNA levels.
Of functional relevance, 1 lM GW4064 signiﬁcantly in-
creased the LDLr activity (+60%, P < 0.001). In correlation
with the PXR-mediated induction of PCSK9, LDLr activity
was conversely reduced by 30% (P < 0.05) in response to
10 lM rifampicin (Fig. 4E). These results suggest that FXR
activation may contribute to the CDCA-mediated repression
of PCSK9 in IHH cells.4. Discussion
Human genetic studies indicate that inhibiting PCSK9 is a
very promising strategy to lower LDL-c [3]. One way to reach
this goal is to decrease the synthesis of PCSK9. Recently, the
administration of an anti-sense oligonucleotide inhibitor tar-
geting PCSK9 in high-fat fed mice led to a 38% decrease of
the plasma LDL-c concentrations [23]. An alternative strategy
is to directly inhibit PCSK9 transcription. In the current study,
we demonstrated for the ﬁrst time that CDCA is a new repres-
sor of PCSK9 gene expression in human hepatocytes. Of func-
tional relevance, the down-regulation of PCSK9 mRNA levels
by CDCA treatment is associated with an increased LDLr
activity. More importantly, CDCA is able to counterbalance
the positive regulation of PCSK9 by pravastatin and therefore
potentiates its stimulating eﬀect on the LDLr activity. CDCA
increases LDLr mRNA levels [20], an eﬀect that should also
contribute to stimulate LDLr activity. In our cellular model,
however, the potentiation of LDLr activity in response to
CDCA and pravastatin combination treatment occurs in the
absence of a further increase of LDLr mRNA levels. This ﬁnd-
ing validates the working hypothesis that coadministration of
a PCSK9 inhibitor may amplify the hypolipidemic eﬀect of
statins.
Amongst the BAs we tested, only the most potent FXR ago-
nist CDCA repressed PCSK9 expression, indicating that the
regulatory pathway might be speciﬁc for this nuclear receptor.
In accordance with this hypothesis, we found that the speciﬁc
synthetic agonist GW4064 reduces PCSK9 mRNA and protein
contents. Moreover, we demonstrate for the ﬁrst time that
GW4064 increases the LDLr activity in vitro. On the other
hand, a contribution of the other signalling pathways induced
by the CDCA in the repression of PCSK9 was excluded. Acti-
vation of PXR leads indeed to an increased PCSK9 expression
and a subsequent decrease of LDLr activity. In addition, treat-
ment with DCA, a more potent ligand than CDCA for the G
protein-coupled cell-surface BA receptor TGR5 [24], moder-
ately increased PCSK9 expression. CDCA has been shown
to increase LDLr mRNA stability by inducing mitogen acti-
vated protein (MAP) kinase signalling pathways, particularly
extracellular-regulated kinases (ERK) 1/2 [20]. Inhibition of
ERK1-2 signalling pathway by the speciﬁc inhibitor U0126
signiﬁcantly reduced PCSK9 mRNA levels (data not shown).
These results indicate that neither the activation of PXR,
TGR5 nor ERK1–2 is involved in the CDCA-mediated repres-
sion of PCSK9.
To deﬁnitively conﬁrm that CDCA-mediated repression of
PCSK9 is FXR-dependent, a FXR-silencing gene experiment
using siRNA was performed. Despite a highly signiﬁcant de-
crease of FXR mRNA levels (80%, P = 0.001) and the abo-lition of CDCA-induced SHP gene expression, the repression
of PCSK9 still occurred in FXR siRNA transfected cells (Sup-
plementary Fig. S1). Therefore, this RNAi mediated approach
failed to abolish the repressive potency of the FXR pathway.
Thus, in addition to FXR activation, it can not be formally ex-
cluded that additional BAs-mediated signalling pathways can
govern CDCA-mediated PCSK9 repression.
In addition, we cannot use the FXR-deﬁcient mouse model
since the CDCA-mediated PCSK9 repression was not retrieved
in primary mouse hepatocytes (data not shown). Such a specie-
speciﬁc regulation in response to FXR was already observed
for many genes involved in lipid metabolism as PPARa [25],
hepatic lipase [26] and syndecan-1 [27]. While actinomycin D
experiments indicate that CDCA acts at the transcriptional
level for repressing PCSK9, additional studies are needed to
precisely assess the molecular mechanism by which CDCA
and GW4064 repress PCSK9 expression.
Very recently, Nilsonn et al. demonstrated that a 3-weeks
treatment with CDCA reduces LDLr mRNA levels in the liver
of subjects who underwent a cholecystectomy for gallstone dis-
ease, while PCSK9 mRNA levels were not altered [28]. Con-
versely, a 3-weeks treatment with cholestyramine, a BA
sequestrant, increased LDLr and PCSK9 mRNA levels by
65% and 70%, respectively. Although this study reinforces
the hypothesis for a cross-talk between BAs and PCSK9, it re-
mains diﬃcult to reconcile these in vivo ﬁndings with our
in vitro data, as well as with previously published results dem-
onstrating that CDCA induces LDLr gene expression in vitro
[20,29]. The reason for this discrepancy remains unclear. How-
ever, it should be noticed that CDCA treatment in these
patients failed to modulate the expression of hepatic FXR-
target genes such as ApoCIII and ApoAI [28].
FXR appears as a promising target to treat dyslipidemia
[12]. CDCA has been shown to reduce triglyceride and
cholesterol levels in the fructose fed hamster model of
metabolic syndrome and combined dyslipidemia [30]. Similar
results were recently reported with a new synthetic FXR ago-
nist in several rodent models of dyslipidemia [31], and phase I
studies in human are in progress (ClinicalTrials.gov Identiﬁer:
NCT00499629 and NCT00509756). Our present results suggest
that part of the hypolipidemic eﬀects of FXR agonists might
be mediated by PCSK9 repression.
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